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Diabetes mellitus is a chronic metabolic disease approximately affect-
ing 6 million adults in Germany and more than 300 million people
worldwide [1]. On average, nearly 8% of adults in high-income coun-
tries and 10% in middle or low-income countries have diabetes [2].
Patients with diabetes have an increased risk for cardiovascular dis-
eases, renal impairments, blindness, peripheral neuropathy and am-
putations of the lower leg and for excess mortality [3]. Unknown or
insufficiently treated diabetes bears a particularly high risk for long-
term complications. Diabetes is associated with a high burden of dis-
ease and costs for individuals as well as for the health care system
and society as a whole. Treatment and care of diabetes led to costs
of almost 48 billion euros in Germany in 2009 [4].
Against this background, the Robert Koch Institute RKI (the German
National Public Health Institute) was commissioned by the Federal
Ministry of Health to develop a National Diabetes Surveillance
System for Germany. In order to integrate existing international ex-
pertise in the development process, the RKI organized an inter-
national workshop with experts from the U.S., Canada and Europe.
The Workshop ‘Development of a National Diabetes Surveillance
System in Germany – Core Indicators and Conceptual Framework’
was held in Berlin, Germany on July 11–12, 2016 and pursued the fol-
lowing goals: (a) to share experience on existing surveillance systems
and diabetes registries (b) to refine the conceptual framework of the
diabetes surveillance in Germany and for harmonization of core in-
dictors and (c) to strengthen international collaboration. Experts were
invited to present their specific experiences in planning and imple-
menting diabetes registries or surveillance approaches (S1-S6). The
conceptual framework and aims of the diabetes surveillance project
in Germany were presented in the first workshop contribution by
Christa Scheidt-Nave, Robert Koch-institute RKI, Berlin Germany (S1).
The U.S. experience in the gradually implementation over the last
20 years of a National Diabetes Surveillance System (USDSS) was pre-
sented by Edward Gregg, epidemiologist at the CDC in Atlanta (S2).
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formation recorded in National Clinical Registries was introduced by
Jan Mainz, member of the Danish National Board of Health (S3). The
development of a National Diabetes Surveillance System (NDSS) in
Canada using administrative health care data available across the
country was presented by Jeffrey Johnson from the School of Public
Health at the University of Alberta (S4). The international approach of
using Health Care Quality Indicators (HCQI) for diabetes at the
European level and within the OECD Health Care Quality Indicator
Project was presented by Fabrizio Carinci, from the School of Health
Sciences in Surrey, UK (S5). Sarah Wild from the Scottish Diabetes
Research Network introduced the population-based Scottish national
diabetes register, which allows daily electronic capture of data from
primary and secondary health care (S6).
References
1. Heidemann C, Du Y, Schubert I, Rathmann W, Scheidt-Nave C (2013).
Prevalence and temporal trend of known diabetes mellitus. Results of the
German Health Interview and Examination Survey for Adults (DEGS1).
Bundesgesundheitsblatt 56:668–677. doi:10.1007/s00103-012-1662-5.
2. Scully T (2012). Diabetes in numbers. Nature, 485(7398), S2-S3.
doi:10.1038/485S2a.
3. ADA (2012). Executive summary: Standards of medical care in diabetes-
2012. American Diabetes Association ADA. Diabetes Care, 35(1):4–10.
doi:10.2337/dc12-s004.
4. Koster I, Schubert I, Huppertz E (2012). [Follow up of the CoDiM-Study:
Cost of diabetes mellitus 2000–2009]. Deutsche Medizinische
Wochenschrift, 137(19): 1013–1016. doi:10.1055/s-0032-1304891.
SPEAKERS PRESENTATIONS
S1
Diabetes Surveillance in Germany – Status quo and Perspectives
Christin Heidemann, Lars Gabrys, Christian Schmidt, Andrea Teti,
Ingrid-Katharina Wolf, Yong Du, Rebecca Paprott, Jens Baumert,
Thomas Ziese, Christa Scheidt-Nave
Department of Epidemiology and Health Monitoring, Robert Koch
Institute, Berlin, Germany
Correspondence: Christa Scheidt-Nave (Scheidt-NaveC@rki.de)
BMC Proceedings 2017, 11(Suppl 3):S1
Over the last years, several programs and action plans targeted at
the prevention and control of diabetes were initiated on the inter-
national [1–2] and national [3–7] level. In 2015, the German Ministry
of Health funded a four year research project to evaluate the feasibil-
ity of a National Diabetes Surveillance System in Germany under thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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System are (1) to build a comprehensive and sustainable database
for Public Health and Health Services Research on diabetes in line
with internationally agreed indicators, (2) to identify and overcome
barriers (e.g. technical, economical, legal, ethical, political barriers) to
data sharing across health sectors, establish a surveillance at the
national and the regional level, (3) to enable evidence-informed
policy advising, and (4) to make diabetes a paradigm for non-
communicable disease surveillance.
In lack of a legal basis for the use of unified patient identifiers, the
framework is conceptualized as a Public Health Surveillance System
that is based on available data from nationwide health surveys of the
Robert Koch Institute as well as secondary data sources from differ-
ent health sectors and research settings (e.g. type 1 diabetes regis-
tries for children and adolescents; information system for health care
data ‘data transparency’; Disease Management Programs on diabetes;
Diagnosis Related Groups statistics for hospital admissions). This large
but fragmented database will be assessed with regard to sustainable
monitoring based on selected diabetes core indicators. A preliminary
set of core indicators was identified based on a review of indicators
used in established diabetes surveillance systems and diabetes regis-
tries in other countries as well as indicators relevant to the German
Disease Management Programs for type 1 and type 2 diabetes. These
core indicators can be assigned to the following four areas of action:
1) ‘Reducing diabetes risk’, 2) ‘Improving diabetes diagnosis and
treatment’, 3) Reducing diabetes complications’, and 4) ‘Reducing the
burden of disease and costs associated with diabetes’. Sociodemo-
graphic variables considered essential for stratified analyses were
added. The initial indicator list was reviewed by national and inter-
national experts with respect to their relevance (essential, important,
additional, or negligible). A continued collaboration is intended for re-
fining the conceptual framework and harmonization of core indictors.
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Chronic disease surveillance systems play several critical roles in the
population-wide reduction of chronic diseases. Surveillance systems
ideally provide efficient monitoring of risk factors, care, the deliveryof preventive interventions, prevalence and incidence, and morbidity,
all of which are applied across sub-segments of the population, and
according to geographic location. When such data is further inte-
grated with findings from intervention effectiveness research and
health impact and economic modeling, it forms the basis for effect-
ive public health decision making and to optimally prioritize ap-
proaches and populations for prevention. The U.S. National Diabetes
Surveillance System (USDSS) was gradually built as an integrated,
multi-component composition of surveys and registries [1]. Primary
information on risk factors, prevalence, and incidence comes from
the National Health Interview Survey (NHIS), Behaviour Risk Factor
Surveillance System (BRFSS), and National Health and Nutrition
Examination Surveys (NHANES). Data on diabetes-related morbidity is
primarily derived from the National Hospital Discharge Survey
(NHDS), National Inpatient Sample (NIS), and specialized registries
like the U.S. Renal Data System, while mortality estimates are esti-
mated using vital statistics data that are linked to population survey
data. Specialized registries such as the SEARCH Study are also used
to assess specific problems such as diabetes in youth [2]. The system
relies largely on a design of serial cross-sections, permitting both
yearly estimates as well as multi-year aggregates. By incorporating
the USDSS into multi-level and Markov modelling, the data are also
used to examine specific geographic variation, and for the estimation
of lifetime risk, disability-free life years lost due to specific conditions,
and for cost-effectiveness modelling of candidate interventions.
Finally, the system has developed practical, interactive data
visualization tools to help leaders and policy makers in public health.
Over the past 20 years, the USDSS has documented several phases
and diverse sub-trends in the population, including the growth of
prevalence and incidence and lifetime risk, improvements in care,
and reductions in diabetes-related complications and mortality, and
has highlighted important variation in all indicators and diversifica-
tion of morbidity that have provided the basis for focused public
health resources and interventions for diabetes [3, 4, 5]. The key surveil-
lance challenges for the future include improving the geographic tex-
ture of measurement of risk, care, and control, improving assessment
of primary prevention behaviors and interventions, improving assess-
ment of risks and adverse events, incorporating electronic medical re-
cords and longitudinal measurements into surveillance of care, and
application of NDSS data into assessment of natural experiments of
health policy interventions. Finally, better standardization of systems
will facilitate multi-national comparisons and better international pool-
ing studies to better tackle the global problem of diabetes.
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benchmarking due to comprehensive information recorded in the
National Clinical Registries. This presentation clarifies the use of these
registries to improve the quality of care provided by the Danish
health care system.
The public and mainly tax-financed Danish health care system pro-
vides universal health coverage to the country’s 5.5 million inhabi-
tants. It is a stated priority, that all citizens should have free and
equal access to health care services [1]. By the use of a unique, ten-
digit civil registration number assigned to all Danish residents, each
contact with the health care system is recorded in National Clinical
Registries. Currently 61 disease-specific registries systematically docu-
ment and develop the quality of care provided by the Danish health
care system by the use of process-, and outcome indicators in ac-
cordance with national clinical guidelines [2, 3]. Reporting is
mandatory for all public hospitals in Denmark ensuring a high cover-
age > 90%. Clinicians and managers at the hospital department and
clinics receive continuous feedback of their adherence to the recom-
mended clinical guidelines. Structured audits are further initiated on
national, regional and local basis to ensure implementation of im-
provements whilst all data are published yearly to inform the public
of the development in the quality of care.
Nationwide studies demonstrate significant improvements since the
initiation of systematic indicator monitoring combined with continu-
ously auditing in the Danish health care system. In this regard, the
adherence to several guidelines recommended process indicators in-
creased between 2004 and 2011 for patients hospitalized with
schizophrenia and between 2003 and 2010 for incident heart failure
patients seen at hospital departments and outpatient clinics [4, 5].
Similar efficiency have been shown in the quality of care for stroke,
high volume cancers, coronary percutaneous coronary intervention/
coronary artery bypass surgery, hernia, childhood diabetes and perfo-
rated gastric ulcer in Denmark. Nevertheless, variation in the deliv-
ered quality of care remains between both the specific disease and
the hospital departments. In conclusion, the quality of care has im-
proved substantially since systematic monitoring and auditing was
initiated in Denmark.
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Using administrative health care utilization data available in all
provinces and territories across the country, Canada developed a
National Diabetes Surveillance System (NDSS) build on federal/
provincial/territorial (F/P/T) partnerships. A series of pilot studies initially
established the validity of a case definition for diabetes based on ICD9
billing codes. The Canadian NDSS reported trends in diabetes incidenceand prevalence in a federated model, coordinated federally by the
Public Health Agency of Canada, with each of the P/T contributing ag-
gregated surveillance data, generated using a common computing syn-
tax. Building on this model the PHAC sponsored work to develop and
test case definitions for other chronic conditions, and the NDSS evolved
into the Canadian Chronic Diseases Surveillance System (CCDSS), with
ongoing surveillance for diabetes, hypertension, selected mental ill-
nesses, and chronic respiratory diseases. National pilot studies have
been conducted for heart disease and musculoskeletal conditions.
Methodological challenges for the CCDSS include lack of completeness
of disease case capture in physician billing claims, poor measurement
validity of diagnosis codes for some chronic conditions, and striking a
balance between reporting all cases with interpretable rates and follow-
ing the latest residual disclosure guidelines. Further, the NDSS/CCDSS
are limited to surveillance of disease incidence, prevalence and mortal-
ity. Further developments are needed, and ongoing in some P/T juris-
dictions, to build on the established administrative data sources to
embellish the available information, and extend surveillance to individ-
ual level risk factors, health status and behaviours. Such efforts would
link survey data to administrative data sources to provide more com-
prehensive risk factor and disease surveillance.
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Continuous monitoring of health care quality indicators (HCQIs) is in-
creasingly seen as an effective solution to steer governments to-
wards high performing health systems. Comparative analysis may
help identifying areas for immediate improvement through mutual
collaboration within organizations e.g. the Organization for Economic
Co-operation and Development (OECD) and the European Union
(EU).
The OECD Framework of Health Systems Performance is a multidi-
mensional matrix adopted for regular publication by 34 Member
States (MS) [1] in which HCQIs have been allocated in a multidimen-
sional quality matrix measuring efficiency, safety and responsiveness
along the life cycle of the individual.
Targeted OECD studies have been conducted to improve HCQIs that
were considered too variable across countries e.g. amputation rates
in diabetes [2]. New definitions were released for Health at a Glance
2015 [3] , where Germany showed a rate of 9.8 major amputations
x100,000 total population, third highest after Israel and Slovenia out
of 17 countries (median: 6.0; range: 1.07-17.05).
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health monitoring: are this data accurate? Is there a problem of het-
erogeneity of data definitions, or instead, are we facing a real clinical
problem on which governments should act? Answers may not be
straightforward without a system in place and indeed, the data deliv-
ered to the OECD are officially provided by the government.
During the last decade, the European Union sponsored specific initia-
tives e.g. the EUBIROD project (www.eubirod.eu) to create a common
EU infrastructure for diabetes monitoring. The project delivered stan-
dardized definitions, privacy rules and the software required to make
it happen [4].
Developing a national surveillance system for a large country e.g.
Germany may be not less challenging than carrying out diabetes
reporting across Europe. A common system would allow: a) saving fi-
nancial resources by avoiding duplications while exploiting the exist-
ing information infrastructure; b) overcoming data protection issues
through the development of a platform that would implement “priv-
acy by design”; c) automatic updating and immediate testing of new
definitions.
The EUBIROD project provided useful criteria that may show how to
proceed in a sustainable direction, adopting a “bazaar model” rather
than proposing a new “cathedral”. Such an approach would allow
reconciling technical aspects with the need to resolve clinical ques-
tions of utmost importance for all citizens. To proceed further,
Germany may need to define the essential level of information first
and then implement the national infrastructure accordingly [5]. Other
countries may directly benefit from the result of such a strategic
initiative.
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The need to develop plans to prevent, identify and treat diabetes and
its complications at local, national and regional levels and the setting of
targets for Europe was first formally identified in the 1989 St Vincent
declaration on the treatment of diabetes. Progress has been made but
full implementation has not been achieved and diabetes prevalencecontinues to rise, along with increasing individual and societal costs of
complications. A national population-based register of people with a
diagnosis of diabetes was set up in Scotland following agreement of a
core dataset and development of earlier local registers. The register is
populated by daily electronic capture of data from primary and second-
ary care and includes demographic, clinical, laboratory, eye screening
and prescribing information and a patient portal. The register became
comprehensive following the introduction of a pay-for-performance
scheme for general practitioners in the United Kingdom, the Quality
and Outcomes Framework [QOF] in 2004. Prevalence of diagnosed dia-
betes in 2015 was 5.3% in the population of Scotland of all ages of
which approximately 90% was type 2 diabetes). Higher prevalence is
observed in men than women, with increasing age (to a maximum of
17% among men of 75–79 years of age) and a marked inverse socio-
economic gradient (prevalence among women in the most-deprived
fifth of the population is double that of women in the least deprived
fifth of the population) [1]. Age-standardised incidence of type 2 dia-
betes has declined in the last decade but prevalence has increased due
to increasing survival [2]. Data linkage to hospital admission, cancer
registration, mortality and other disease registers is possible with per-
mission from the national Public Benefit and Privacy Panel. Examples of
analyses of linked data includes the following findings: that hospital re-
cords under-estimate diabetes prevalence by over 40% [3], that type 2
diabetes is associated with approximately 50% higher mortality than
the general population[1], that type 1 diabetes is associated with the
loss of about 12 years of life expectancy among 20 year olds [4] and
that relative risks of cancer associated with diabetes are similar to those
observed for obesity [5]. Approaches to improving outcomes for people
with diabetes have been addressed in the Scottish Government’s recent
Diabetes Improvement Plan
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